Detalles de la búsqueda
1.
Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease.
J Mark Access Health Policy
; 12(2): 35-57, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38660414
2.
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Front Public Health
; 9: 754482, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34900902
3.
Gene therapy randomised clinical trials in Europe - a review paper of methodology and design.
J Mark Access Health Policy
; 8(1): 1847808, 2020 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33312456
4.
Why "American Patients First" is likely to raise drug prices outside of the United States.
J Mark Access Health Policy
; 7(1): 1650596, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31489151
5.
Patient-reported outcome claims in European and United States orphan drug approvals.
J Mark Access Health Policy
; 6(1): 1542920, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30425804
6.
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration.
J Mark Access Health Policy
; 6(1): 1433426, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29785254
7.
Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
J Mark Access Health Policy
; 5(1): 1412753, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29321830
Resultados
1 -
7
de 7
1
Próxima >
>>